What are the safety and efficacy of atomoxetine in treating ADHD in children under 5 years old?

Read full text Summarise with VIRAT
Authors: Tripdatabase
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Atomoxetine is not approved for children under 6, with limited evidence available regarding its safety and efficacy in this population; non-pharmacologic interventions are usually preferred.

Fields of Study & Subjects

Attention Deficit Hyperactivity Disorder Pharmaceutical studies and practices Child and Adolescent Psychosocial and Emotional Development

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN